NeoGenomics has announced its financial guidance for 2025, projecting total revenues between $735 million and $745 million, marking an anticipated year-over-year growth of 11% to 13% from 2024. This optimistic outlook is driven by the company's strategic focus on product innovation and operational efficiencies, as well as its commitment to expanding its leadership in oncology testing. CEO Chris Smith highli
NeoGenomics experienced a significant downgrade from Benchmark, which shifted its rating from "buy" to "hold," citing the stock as fairly valued at its current levels. This downgrade comes despite the company's recent positive financial performance, including a 10% increase in consolidated revenue and a 305% improvement in adjusted EBITDA for the third quarter of 2024. The downgrade by Benchmark suggests th
NeoGenomics is experiencing a significant drop in its stock price following the announcement that CEO Chris Smith will retire effective April 1, 2025, with board member Tony Zook set to take over the role. Smith, who has been at the helm since August 2022, has been credited with transforming the company, achieving eight consecutive quarters of double-digit revenue growth, and turning around its financial pe
NeoGenomics, Inc. (NEO) stock experienced a decline in after-hours trading, primarily influenced by broader market movements following the Federal Reserve's recent announcements. The Fed's decision to cut interest rates by 25 basis points was anticipated, but the revelation of a more cautious outlook for 2025, with only two expected rate cuts instead of four, unsettled investors. This shift in monetary poli